E7046 Inhibitor

Name: E7046 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5764283
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764283

E7046 is a specific, orally bioavailable EP4 antagonist (IC50: 13.5nM, Ki: 23.14nM), exhibiting anti-tumor activities. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

E7046, Inhibitor

Full Product Name

E7046

Product Gene Name

E7046, inhibitor

Form/Format

Solid. Powder

Purity/Purification

99.09%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

483.40

Solubility

DMSO: 100mg/mL (206.87mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C22H18F5N3O4

SMILES

C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)nn1C)c1Oc1cccc(C(F)(F)F)c1)=O

CAS Number

1369489-71-3

In Vitro

E7046 (150mg/kg) inhibits the growth of multiple syngeneic tumor models. The blockade of EP4 signaling promotes anti-tumor DC differentiation and slows tumor growth in mice. E7046 treatment,reduces the growth or even rejected established tumors in vivo in a manner dependent on both myeloid and CD8C T cells [1]. In the CT-26 tumor model, the E7046/RT combination causes the anti-tumor memory response of 9 animals. In the 4T1 model, the combination of E7046 and RT also produces significantly better tumor growth inhibition activity compared with each treatment, alone. The combination significantly improves survival by inhibiting the subsequent spontaneous lung metastasis of 4T1 tumors [2].

Product Categories/Family for E7046, inhibitor

GPCR/G Protein; Prostaglandin Receptor

Product References and Citations for E7046, inhibitor

Diana I. Albu, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. OncoImmunology.
Diana I. Albu, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. OncoImmunology.
X. Bao, et al. Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology Biology Physics
X. Bao, et al. Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology Biology Physics

Other Notes

Small volumes of E7046, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for E7046 purchase

MBS5764283 is an inhibitor targeting E7046.